A blinded, randomized, placebo‐controlled trial of the safety of lokivetmab (<scp>ZTS</scp>‐00103289), a caninized anti‐canine <scp>IL</scp>‐31 monoclonal antibody in client‐owned dogs with atopic dermatitis

Abstract

Among a diverse population of 162 client owned dogs with a clinical diagnosis of AD, treatment with two monthly doses of lokivetmab was safe, based on observed adverse events and clinical pathology results over a 42 day period.